Skip to content

SmallCap Round Up: Sancus Lending, Fusion Antibodies, Versarien

SmallCap Round Up: Sancus Lending, Fusion Antibodies, Versarien

London’s AIM Index nudged a little higher today with renewed confidence being seen off the back of this morning’s US inflation print, although the prospect of yet more policy tightening at the Bank of England pushed cable close to fresh highs for the year. At the close the index had gained almost three and a half points on the day to stand at 795.88

  • Sancus Lending +77%
  • Fusion Antibodies +26%
  • Versarien +25%
  • Mirada -25%
  • Purplebricks -25%

Sancus LON:LEND was top of our note at lunchtime on Monday and has pushed significantly higher in today’s trade, too. There have however been a couple of updates out, including stake building and a PDMR buy order. A significantly elevated volume was noted on the day, although the spread was pushed out to 30% as a result.


Fusion Antibodies LON:FAB advanced 26% on the day, with two significant stakes now having been disclosed in the company since the start of the week, something which is managing to show the stock some love after the beating it took last month.

Versarien LON:VRS gets the notable mention. Last week’s earnings news clearly missed expectations but bargain hunters appear to be moving in, extending the rollercoaster ride for the stock.

Mirada LON:MIRA was the biggest loser, some 25% off at the bell. However there has been very little trade and the stock sits on an incredibly wide spread as the market cap continues to plummet.

Purplebricks LON:PURP wasn’t far short as the second worst performer, shedding almost 25%. The stock is set to be delisted later in the week, so no surprise that trade is very one sided and the spread is suitably wide, too.

Share this article

Invest with these platforms

Hargreaves Lansdown

IG

Interactive Brokers

Interactive Investor

Charles Stanley

IG

Interactive Brokers

Charles Stanley

Looking for great investing ideas? Get our free newsletter.

This article does not constitute investment advice.  Do your own research or consult a professional advisor.

Learn with our free 'How to' Guides

Our latest in-depth company reports

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

Aquis
CME Group
FP Markets
Pepperstone
Schroders

aberdeen
WisdomTree
ARK
Plus500
CMC Markets
Back To Top